Overview Dividends

(PTCT) PTC Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US69366J2006

Translarna, Emflaza, Upstaza, Evrysdi, Sepiapterin

EPS (Earnings per Share)

EPS (Earnings per Share) of PTCT over the last years for every Quarter: "2020-09": -1.03, "2020-12": -1.08, "2021-03": -1.83, "2021-06": -1.68, "2021-09": -1.89, "2021-12": -2.03, "2022-03": -1.78, "2022-06": -2.13, "2022-09": -1.53, "2022-12": -1.89, "2023-03": -1.88, "2023-06": -2.66, "2023-09": -1.76, "2023-12": -0.24, "2024-03": -1.2, "2024-06": -1.27, "2024-09": -1.39, "2024-12": -0.3416, "2025-03": 10.04, "2025-06": -0.83, "2025-09": 0.2,
EPS Growth (3y CAGR): 54.61%
EPS Trend (3y Corr): 58.4%
Last SUE: 0.34σ
Qual. Beats: 0

Revenue

Revenue of PTCT over the last years for every Quarter: 2020-09: 118.404, 2020-12: 118.864, 2021-03: 117.942, 2021-06: 116.676, 2021-09: 138.743, 2021-12: 165.229, 2022-03: 148.735, 2022-06: 165.526, 2022-09: 217.127, 2022-12: 167.412, 2023-03: 220.382, 2023-06: 213.808, 2023-09: 196.576, 2023-12: 307.056, 2024-03: 210.118, 2024-06: 186.704, 2024-09: 196.786, 2024-12: 213.172, 2025-03: 1176.096, 2025-06: 178.875, 2025-09: 211.007,
Revenue Growth (3y CAGR): 8.78%
Revenue Trend (3y Corr): 27.8%
Last SUE: 0.12σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 60.3%
Value at Risk 5%th 74.4%
Relative Tail Risk -24.98%
Reward TTM
Sharpe Ratio 1.43
Alpha 83.22
Character TTM
Hurst Exponent 0.378
Beta 0.924
Beta Downside 0.924
Drawdowns 3y
Max DD 69.42%
Mean DD 27.98%
Median DD 27.17%

Description: PTCT PTC Therapeutics November 08, 2025

PTC Therapeutics (NASDAQ:PTCT) is a U.S.-based biopharma focused on rare-disease medicines for children and adults, commercializing products such as Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (Kebilidi) for aromatic L-amino-acid decarboxylase deficiency, Tegsedi and Waylivra for other orphan indications, and Evrysdi for spinal muscular atrophy.

The pipeline includes Sepiapterin for phenylketonuria, the PTC518 splice-modulation platform targeting Huntington’s disease (in collaboration with Novartis), and inflammation/ferroptosis programs such as vatiquinone for Friedreich’s ataxia.

Key operational metrics (as of the latest 10-Q) show a 2024 revenue run-rate of roughly $420 million, driven primarily by Evrysdi, with a gross margin of ~78 % and cash on hand of $650 million, giving the company > 12 months of runway without additional financing.

Sector-wide, rare-disease biotech firms benefit from higher pricing power and faster FDA pathways (e.g., orphan-drug and accelerated approvals), but they remain sensitive to payer reimbursement trends and the success of gene-therapy pricing reforms.

For analysts looking to deepen their valuation framework, ValueRay’s interactive model provides granular scenario analysis of PTCT’s pipeline milestones and payer-mix assumptions-worth a look before forming a price target.

PTCT Stock Overview

Market Cap in USD 6,070m
Sub-Industry Biotechnology
IPO / Inception 2013-06-20
Return 12m vs S&P 500 62.9%
Analyst Rating 4.0 of 5

PTCT Dividends

Currently no dividends paid

PTCT Growth Ratios

Metric Value
CAGR 3y 24.62%
CAGR/Max DD Calmar Ratio 0.35
CAGR/Mean DD Pain Ratio 0.88
Current Volume 1479.8k
Average Volume 1022.9k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (751.7m TTM) > 0 and > 6% of Revenue (6% = 106.7m TTM)
FCFTA 0.26 (>2.0%) and ΔFCFTA 41.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 64.16% (prev 74.48%; Δ -10.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.27 (>3.0%) and CFO 715.5m <= Net Income 751.7m (YES >=105%, WARN >=100%)
Net Debt (1.82b) to EBITDA (911.8m) ratio: 2.00 <= 3.0 (WARN <= 3.5)
Current Ratio 2.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (87.1m) change vs 12m ago 13.25% (target <= -2.0% for YES)
Gross Margin 91.20% (prev 83.63%; Δ 7.57pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 79.32% (prev 48.89%; Δ 30.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 6.37 (EBITDA TTM 911.8m / Interest Expense TTM 138.1m) >= 6 (WARN >= 3)

Altman Z'' 0.92

(A) 0.43 = (Total Current Assets 2.01b - Total Current Liabilities 866.2m) / Total Assets 2.64b
(B) -1.07 = Retained Earnings (Balance) -2.83b / Total Assets 2.64b
warn (B) unusual magnitude: -1.07 — check mapping/units
(C) 0.39 = EBIT TTM 879.1m / Avg Total Assets 2.24b
(D) -1.01 = Book Value of Equity -2.82b / Total Liabilities 2.80b
Total Rating: 0.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.51

1. Piotroski 7.0pt
2. FCF Yield 10.20%
3. FCF Margin 39.29%
4. Debt/Equity -16.00
5. Debt/Ebitda 2.00
7. RoE -182.7%
8. Rev. Trend 27.83%
9. EPS Trend 58.36%

What is the price of PTCT shares?

As of November 21, 2025, the stock is trading at USD 76.46 with a total of 1,479,825 shares traded.
Over the past week, the price has changed by +2.01%, over one month by +11.85%, over three months by +56.52% and over the past year by +82.22%.

Is PTCT a buy, sell or hold?

PTC Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PTCT.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the PTCT price?

Issuer Target Up/Down from current
Wallstreet Target Price 80.5 5.3%
Analysts Target Price 80.5 5.3%
ValueRay Target Price 84.7 10.7%

PTCT Fundamental Data Overview November 21, 2025

Market Cap USD = 6.07b (6.07b USD * 1.0 USD.USD)
P/E Trailing = 8.9256
P/E Forward = 6.006
P/S = 3.4116
P/B = 1743.2734
P/EG = 0.81
Beta = 0.493
Revenue TTM = 1.78b USD
EBIT TTM = 879.1m USD
EBITDA TTM = 911.8m USD
Long Term Debt = 2.11b USD (from longTermDebt, last fiscal year)
Short Term Debt = 561.4m USD (from shortTermDebt, last quarter)
Debt = 2.49b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.82b USD (from netDebt column, last quarter)
Enterprise Value = 6.85b USD (6.07b + Debt 2.49b - CCE 1.71b)
Interest Coverage Ratio = 6.37 (Ebit TTM 879.1m / Interest Expense TTM 138.1m)
FCF Yield = 10.20% (FCF TTM 699.0m / Enterprise Value 6.85b)
FCF Margin = 39.29% (FCF TTM 699.0m / Revenue TTM 1.78b)
Net Margin = 42.25% (Net Income TTM 751.7m / Revenue TTM 1.78b)
Gross Margin = 91.20% ((Revenue TTM 1.78b - Cost of Revenue TTM 156.5m) / Revenue TTM)
Gross Margin QoQ = 45.05% (prev 93.62%)
Tobins Q-Ratio = 2.59 (Enterprise Value 6.85b / Total Assets 2.64b)
Interest Expense / Debt = 1.31% (Interest Expense 32.6m / Debt 2.49b)
Taxrate = 168.9% (out of range, set to none) (-39.0m / -23.1m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.32 (Total Current Assets 2.01b / Total Current Liabilities 866.2m)
Debt / Equity = -16.00 (negative equity) (Debt 2.49b / totalStockholderEquity, last quarter -155.8m)
Debt / EBITDA = 2.00 (Net Debt 1.82b / EBITDA 911.8m)
Debt / FCF = 2.60 (Net Debt 1.82b / FCF TTM 699.0m)
Total Stockholder Equity = -411.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.43% (Net Income 751.7m / Total Assets 2.64b)
RoE = -182.7% (negative equity) (Net Income TTM 751.7m / Total Stockholder Equity -411.5m)
RoCE = 51.78% (EBIT 879.1m / Capital Employed (Equity -411.5m + L.T.Debt 2.11b))
RoIC = 1253 % (out of range, set to none) (EBIT 879.1m / (Assets 2.64b - Curr.Liab 866.2m - Cash 1.71b))
WACC = 6.68% (E(6.07b)/V(8.56b) * Re(9.42%) + (debt cost/tax rate unavailable))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.41%
[DCF Debug] Terminal Value 65.91% ; FCFE base≈699.0m ; Y1≈485.9m ; Y5≈249.0m
Fair Price DCF = 48.13 (DCF Value 3.86b / Shares Outstanding 80.3m; 5y FCF grow -35.75% → 3.0% )
EPS Correlation: 58.36 | EPS CAGR: 54.61% | SUE: 0.34 | # QB: 0
Revenue Correlation: 27.83 | Revenue CAGR: 8.78% | SUE: 0.12 | # QB: 0

Additional Sources for PTCT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle